Ontology highlight
ABSTRACT: Background
The evidence supporting the use of trastuzumab (T) in a metastatic setting comes from studies that included (almost) only patients who never received prior T. We investigated the effectiveness of T as first-line therapy for metastatic breast cancer (mBC) in women previously treated with T in the adjuvant setting.Materials and methods
By using record linkage of five administrative health care databases of Lombardy, Italy, we identified 2,046 women treated with T for early breast cancer (eBC) in 2006-2009, 96 of whom developed a metastasis and were retreated with T in first-line treatment for mBC (treatment group). We compared the overall survival (OS) of these women with that of 197 women treated with T in first-line treatment for mBC, who were treated with therapies other than T for early disease (control group). We computed Kaplan-Meier 2-year OS and used a proportional hazard model to estimate the multivariate hazard ratio (HR) of death in the intervention group compared with the control group, adjusted by age, use of endocrine therapy, and site of metastasis.Results
Two-year OS was 60.0% in the treatment group and 59.5% in the control group. The adjusted HR of death in the treatment group compared with the control group was 0.79 (95% confidence interval, 0.50-1.26).Conclusion
Our data provide convincing evidence that the outcome of women receiving first-line T treatment for mBC after T failure in the adjuvant setting is comparable to that of women not receiving T for eBC. These data are of specific interest, given the unavailability of data from randomized clinical trials.
SUBMITTER: Negri E
PROVIDER: S-EPMC4257745 | biostudies-literature | 2014 Dec
REPOSITORIES: biostudies-literature
Negri Eva E Zambelli Alberto A Franchi Matteo M Rossi Marta M Bonifazi Martina M Corrao Giovanni G Moja Lorenzo L Zocchetti Carlo C La Vecchia Carlo C
The oncologist 20141029 12
<h4>Background</h4>The evidence supporting the use of trastuzumab (T) in a metastatic setting comes from studies that included (almost) only patients who never received prior T. We investigated the effectiveness of T as first-line therapy for metastatic breast cancer (mBC) in women previously treated with T in the adjuvant setting.<h4>Materials and methods</h4>By using record linkage of five administrative health care databases of Lombardy, Italy, we identified 2,046 women treated with T for ear ...[more]